After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...